The WACC of Biosynex SA (ALBIO.PA) is 4.6%.
| Range | Selected | |
| Cost of equity | 4.30% - 14.40% | 9.35% |
| Tax rate | 16.80% - 25.00% | 20.90% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 4.2% - 5.1% | 4.6% |
| Category | Low | High |
| Long-term bond rate | 3.0% | 3.5% |
| Equity market risk premium | 5.8% | 6.8% |
| Adjusted beta | 0.14 | 1.45 |
| Additional risk adjustments | 0.5% | 1.0% |
| Cost of equity | 4.30% | 14.40% |
| Tax rate | 16.80% | 25.00% |
| Debt/Equity ratio | 6.99 | 6.99 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 4.2% | 5.1% |
| Selected WACC | 4.6% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ALBIO.PA:
cost_of_equity (9.35%) = risk_free_rate (3.25%) + equity_risk_premium (6.30%) * adjusted_beta (0.14) + risk_adjustments (0.75%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.